Clinical Trials of Antiangiogenic Agents in Epithelial Ovarian Cancer: A Review

抗血管新生藥物在卵巢上皮癌的臨床實驗回顧

劉錦成(Kim-Seng Law)

《童綜合醫學雜誌》 7卷2期 (2013/12) Pp. 37-43

摘要

新生血管在腫瘤惡化，轉移以及腹水的形成上扮演了關鍵性的角色。臨床實驗上針對特定血管新生因子如血管上皮生長因子，血管上皮生長因子接受體，血小板相關生長因子，纖維細胞相關生長因子而研發出來的藥物在治療卵巢上皮癌時無論是應用在輔助性或維持性治療上都有著長足的進步。我們針對抗血管新生因子藥物的臨床實驗在治療卵巢上皮癌不論是初始或復發情境下的主要以及次要臨床指標作了一整理，也探討了此藥物在治療上的好處以及可能的缺失。

關鍵字

血管新生 ； 卵巢上皮癌生長因子

並列摘要

Angiogenesis plays a vital role in the development of tumor progression and metastasis as well as ascitic formation.Several clinical trials with agents targeting the specific angiogenic factors such as the vascular epithelial growth factors(VEGF), vascular epithelial growth factor receptor (VEGFR), platelets -derived growth factors (PDGF) and fibroblast -derived growth factors (FDGF) has gained major progression in the setting of adjuvant and maintenance treatment of epithelial ovarian cancer. We summarize the clinical trials of the antiangiogenic agents with focusing on the primary end points as well as the secondary end points in the primary as well as recurrent settings and discuss the benefits and probable limitations of this agents in the treatment of epithelial ovarian cancer.

並列關鍵字

Angiogenesis ； Epithelial Ovarian Cancer Vascular epithelial growth factor